Roche Returns To Cystic Fibrosis Fray With Enterprise Deal
Paying £75m Upfront to UK Biotech
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
